ANGO Stock Overview
A medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ANGO from our risk checks.
AngioDynamics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.74 |
| 52 Week High | US$8.25 |
| 52 Week Low | US$5.26 |
| Beta | 0.67 |
| 11 Month Change | 3.06% |
| 3 Month Change | -10.25% |
| 1 Year Change | -1.61% |
| 33 Year Change | -76.64% |
| 5 Year Change | -56.46% |
| Change since IPO | -46.08% |
Recent News & Updates
Recent updates
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Jul 19
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified
Jul 18AngioDynamics: A Story To Monitor
May 14A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Apr 09AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
Apr 06AngioDynamics: Restructuring Initiative May Not Go Far Enough
Jan 14AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 12AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt
Mar 31AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance
Oct 06AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold
Sep 29Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?
Sep 02AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M
Jul 12Shareholder Returns
| ANGO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.6% | -0.4% | -1.0% |
| 1Y | -1.6% | 20.3% | 30.3% |
Return vs Industry: ANGO underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: ANGO underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| ANGO volatility | |
|---|---|
| ANGO Average Weekly Movement | 7.4% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANGO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANGO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 748 | Jim Clemmer | www.angiodynamics.com |
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure.
AngioDynamics, Inc. Fundamentals Summary
| ANGO fundamental statistics | |
|---|---|
| Market cap | US$273.06m |
| Earnings (TTM) | -US$243.03m |
| Revenue (TTM) | US$292.73m |
0.9x
P/S Ratio-1.1x
P/E RatioIs ANGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANGO income statement (TTM) | |
|---|---|
| Revenue | US$292.73m |
| Cost of Revenue | US$141.36m |
| Gross Profit | US$151.36m |
| Other Expenses | US$394.39m |
| Earnings | -US$243.03m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.98 |
| Gross Margin | 51.71% |
| Net Profit Margin | -83.02% |
| Debt/Equity Ratio | 0% |
How did ANGO perform over the long term?
See historical performance and comparison